Angel to provide regenerative medicine development services  19 Nov 2009

ANGEL BIOTECHNOLOGY HOLDINGS PLC (Angel or the Company)

Angel to provide regenerative medicine development services

Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, is pleased to announce that is had been named as a contractor on three independent grants that have been awarded to three separate consortia of UK companies active in the field of regenerative medicine. Under the terms of each of the awarded grants, Angel will provide biomanufacturing services at commercial rates to the three consortia. Details of the consortia and the grants awarded have not been disclosed.

Whilst the financial value of the grants to Angel is limited, Angel's position as a contractor to the three groups demonstrates that its expertise in cell-based therapies makes it the natural choice as a manufacturing partner in a field of product research and development that is currently receiving high priority from grant awarding bodies.

Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings plc, said:  "Angel Biotechnology is the only manufacturer within the UK to offer fully integrated process development services and cGMP manufacturing for cell therapy products.  Angel has been involved in the GMP manufacture of cell based therapies and stem cells since 2005 and is at the forefront in the GMP manufacture of these emerging technologies.  We have built a great deal of experience through commercial contracts and grant aided research to produce GMP compliant cell banks and cells for use in clinical trials with eminent development companies in the field.  We are delighted that our expertise and experience have been acknowledged by these grant recipient companies naming Angel as a subcontractor for regenerative medicine services.

For further information, please call:
Angel Biotechnology Holdings plc Tel: +44 (0) 131 445 6077
Gordon Sherriff COO Tel: +44 (0) 7951 057016
 
Grant Thornton Corporate Finance Tel: +44 (0)20 7383 5100
Philip Secrett/Colin Aaronson 
 
Matrix Corporate Capital LLP Tel +44 (0) 20 3206 7000
Steve Cox/Steve Waterman                                
 
About Angel Biotechnology Holdings plc
Angel Biotechnology Holdings plc is a biomanufacturing company offering process development services and GMP manufacturing for advanced biologics, supporting biotechnology and pharmaceutical companies worldwide.  Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.  Angel specializes in the provision of advanced biologics; these include autologous and allogeneic cell therapy products, stem cells, cellular vaccines, specific purified natural and recombinant proteins and bacteriophage.  Angel is managed by a team with wide ranging experience in biopharmaceutical manufacture, gained in companies such as Glaxo, Johnson and Johnson, Serologicals Inc., PPL Therapeutics and Intercell Ag.

Angel was admitted to trading on AIM in November 2005. More information about the Company can be found at www.angelbio.com.